KIMS Hospital Collaborates with Pfizer India to Establish CoE for Adult Vaccination

The newly inaugurated centre will reinforce immunisation against various vaccine-preventable diseases such as Pneumococcal disease, hepatitis A and B, human papillomavirus (HPV), and influenza.

Global pharma player, Pfizer India has collaborated with Krishna Institute of Medical Sciences (KIMS) Hospital to establish a centre of excellence (CoE) for adult vaccination in Hyderabad. The centre was inaugurated by Dr Bhaskar Rao, CMD, KIMS Hospitals.

This strategic collaboration seeks to promote and enhance the adoption of adult vaccination within the local community to protect patients against vaccine-preventable diseases (VPDs).

The newly inaugurated centre will reinforce immunisation against various vaccine-preventable diseases such as Pneumococcal disease, hepatitis A and B, human papillomavirus (HPV), and influenza.

Further, it will facilitate equipping healthcare professionals (HCPs) and educating patients about the long-lasting benefits of vaccination for individuals with comorbidities, advanced age, occupational hazards, and lifestyle-related disorders.

Sharing his views, Dr Santosh Taur, director, Medical Affairs, Vaccines & Digital, Pfizer, said, "The upsurge in chronic respiratory illnesses and air pollution in major cities heightens susceptibility to infectious diseases like pneumococcal infections and influenza. Vaccination stands as a proven and effective preventive measure against pneumococcal disease."

Founded in 1973, Krishna Institute of Medical Sciences (KIMS) Hospital is a private hospital located in Hyderabad. The hospital aims to provide quality healthcare services to patients and is equipped with advanced medical facilities.

Expressing his views, Dr VV Ramana Prasad, consultant pulmonologist, intensivist and sleep specialist, KIMS Hospitals, said, "Respiratory illnesses pose substantial global challenges, and we have a commitment to patients not only for treatment but prioritisation of vaccination. The emphasis on adult vaccination is instrumental in enhancing overall quality of life, especially in combating infectious diseases. Through our collaboration with Pfizer, we aim to reach a wider audience in Hyderabad and Telangana, fostering awareness and widespread adoption of adult vaccination."

Pfizer India was established in 1950, as a subsidiary of Pfizer Inc., a global pharmaceutical company headquartered in New York, USA. Pfizer aims to improve the health and well-being of people around the world by discovering, developing, and manufacturing innovative medicines, vaccines, and consumer healthcare products.

In a similar development, Evaxion’s AI-powered Vaccine Discovery Platform ‘Eden’ receives validation. The platform is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current advanced methods. With its AI platform Eden, Evaxion sought to take a novel approach to vaccine development to combat the rising global issue of antibiotic resistance.

Last month, Gingo Bioworks partnered with Pfizer to discover RNA-based drug candidates. Under this partnership, Pfizer will harness Ginkgo’s exclusive RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.